Literature DB >> 19074974

Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Koji Abe1, Arlene S Bridges, Kim L R Brouwer.   

Abstract

Previous reports have indicated that in vitro biliary clearance (Cl(biliary)) determined in sandwich-cultured hepatocytes correlates well with in vivo Cl(biliary) for limited sets of compounds. The purpose of this study was 1) to determine the in vitro Cl(biliary) in sandwich-cultured human hepatocytes of angiotensin II receptor blockers and HMG-CoA reductase inhibitors that undergo limited metabolism and 2) to compare the predicted Cl(biliary) values with estimated in vivo hepatic clearance data in humans. The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively. Cl(biliary) values predicted from sandwich-cultured human hepatocytes correlated with estimated in vivo hepatic clearance values based on published data (no in vivo data in humans was available for pitavastatin), and the rank order was also consistent. In conclusion, in vitro Cl(biliary) determined in sandwich-cultured human hepatocytes can be used to predict in vivo Cl(biliary) of compounds in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074974      PMCID: PMC2680516          DOI: 10.1124/dmd.108.023465

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  29 in total

1.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

Authors:  D Nakai; R Nakagomi; Y Furuta; T Tokui; T Abe; T Ikeda; K Nishimura
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.

Authors:  Wakaba Yamashiro; Kazuya Maeda; Masakazu Hirouchi; Yasuhisa Adachi; Zhuohan Hu; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-19       Impact factor: 3.922

3.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

4.  OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

Authors:  Rie Nakagomi-Hagihara; Daisuke Nakai; Kenji Kawai; Yasushi Yoshigae; Taro Tokui; Takaaki Abe; Toshihiko Ikeda
Journal:  Drug Metab Dispos       Date:  2006-02-24       Impact factor: 3.922

5.  A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.

Authors:  Robert J Riley; D F McGinnity; R P Austin
Journal:  Drug Metab Dispos       Date:  2005-06-02       Impact factor: 3.922

6.  Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats.

Authors:  X Liu; J P Chism; E L LeCluyse; K R Brouwer; K L Brouwer
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

7.  Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.

Authors:  D M Colussi; C Parisot; M L Rossolino; L A Brunner; G Y Lefèvre
Journal:  J Clin Pharmacol       Date:  1997-03       Impact factor: 3.126

8.  In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

Authors:  G Ghibellini; L S Vasist; E M Leslie; W D Heizer; R J Kowalsky; B F Calvo; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2007-01-18       Impact factor: 6.875

9.  SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  I Ieiri; S Suwannakul; K Maeda; H Uchimaru; K Hashimoto; M Kimura; H Fujino; M Hirano; H Kusuhara; S Irie; S Higuchi; Y Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2007-04-25       Impact factor: 6.875

10.  Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium.

Authors:  G W Sandker; B Weert; P Olinga; H Wolters; M J Slooff; D K Meijer; G M Groothuis
Journal:  Biochem Pharmacol       Date:  1994-06-15       Impact factor: 5.858

View more
  19 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

3.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

Review 4.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

5.  Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates.

Authors:  Brian C Ferslew; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2014-02-22       Impact factor: 4.849

Review 6.  Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Authors:  Hannah M Jones; Kapil Mayawala; Patrick Poulin
Journal:  AAPS J       Date:  2012-12-27       Impact factor: 4.009

7.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

8.  Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Authors:  Hee Eun Kang; Melina M Malinen; Chitra Saran; Paavo Honkakoski; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

9.  Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.

Authors:  Brandon Swift; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

10.  Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.

Authors:  Wei Yue; Koji Abe; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.